Athersys is planning a stock sale to raise operating cash

For months, the Cleveland-based regenerative medicine company has been restructuring its operations and trying to raise the cash it needs to complete the testing and commercialization of its adult stem cell therapy, MultiStem.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.